Ambavizumab injection is usually combined with romisvirizumab for treatment. Ambavizumab injection is a neocoronavirus therapeutic drug, clinically used in combination with lomivizumab by intramuscular injection, mainly used for adults and adolescents with neocoronavirus of mild and common type with high-risk factors for progression to severe type (including hospitalization or death). Adolescent patients must be 12-17 years of age and weigh ≥40 kg, otherwise they cannot be treated with ambavizumab injection and will need to change to another treatment regimen. Patients may experience diarrhea, elevated blood pressure, pain, and decreased sense of taste during the course of the medication; in addition, patients with renal or hepatic impairment should use the drug with caution. The use of this drug should follow the instructions of the doctor, and should not be used on its own.